Form 4 for NMRA Neumora Therapeutics, Inc.
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0001610717-24-000065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-16 | 2024-02-14 | NMRA | Gosebruch Henry O | Pres, CEO, Dir | A - Grant | $0.00 | +80.0K | 462.3K | +21% | $0 |
| D | 2024-02-16 | 2024-02-14 | NMRA | Gosebruch Henry O | Pres, CEO, Dir | A - Grant | $0.00 | +160.0K | 160.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | A | A | 80,000 | $0.00 | 462,345 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-14 | A | A | 160,000 | $0.00 | 160,000 | D | $18.07 · — to 2034-02-13 | 160,000 Common Stock | (F4) 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |